Mineralys Therapeutics, Inc. (MLYS) Tops Q4 EPS by 54c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.40), $0.54 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Robinhood Ventures Fund II opens at $22.50, IPO at $25
• Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions
• Home Depot (HD) call put ratio 1 call to 1 put into quarter results